03.

Investors

Here you will find financial calendar, reports, information about the share and corporate governance

Change of Trading place 2020

Financial calendar

Q1 report, 2020
31 January, 2020
Q2 report, 2020
29 April, 2020
Q3 report, 2020
31 July, 2020
Year End Report 2020
30 October, 2020
Annual General Meeting
December, 2020

Financial reports

2020

2019

2018

2017

2016

2015

Corporate Governance

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as per August 31, 2020:

‍‍

Owner
Shares
Percentage
Diamyd Medical AB
2,998,703
12.82
Anders Essen-Möller
2,279,562
9.74
Avanza Pension
1,787,705
7.64
Polski Bank Komorek Macierzystych
760,819
3.25
Bertil Lindqvist
701,950
3.00
Robert Joki
603,665
2.58
Pabros AB (previously MabTech Group AB)
593,217
2.54
Nordnet Pensionsförsäkring AB
471,740
2.02
BioAll AB**
467,931
2.00
Konstruktions och försäljningsaktiebolaget
438,888
1.88
Total
11.104.180
47.47
* In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.98 percent managed by Avanza Pension.

** BioAll AB is controlled by CEO Mathias Svahn and his relatives. This item also includes Mathias Svahn's directly registered holdings of 0.29 percent and holdings managed through Nordnet Pensionsförsäkring of 0.11 percent.

Trading information

NextCell Pharma AB is listed on the Nasdaq First North Growth Market since July 2020. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Nasdaq First North website:

Nasdaq OMX Nordic

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.

Archived documents